

Qian Xu<sup>1†</sup>, Jia Wang<sup>2,4†</sup>, Zhuangqi Li<sup>1</sup>, Xuanwen Ding<sup>2,3</sup>, Chao He<sup>4\*</sup>, Zhongyu Wei<sup>2,3\*</sup>, Bao Liu<sup>1\*</sup>

1. Department of Health Economics, School of Public Health, Fudan University, 200032, Shanghai, China  
2. Shanghai Innovation Institute, 200231, Shanghai, China

3. School of Data Science, Fudan University, 200433, Shanghai, China  
4. Shanghai Key Laboratory of Rail Infrastructure Durability and System Safety, Tongji University, 201804, Shanghai, China

## Background

- Initiated in 2018, China's National Volume-Based Drug Procurement (NVBP) represents a landmark reform in pharmaceutical pricing, achieving substantial cost reductions through centralized competitive bidding<sup>[1-3]</sup>.
- To date, the number of procured drug varieties has reached 490, with an average price reduction of more than 50%. By 2023, centralized procurement of pharmaceutical products had saved over 500 billion yuan<sup>[4]</sup>.
- NVBP constitutes a complex system scenario involving multi-stakeholder strategic interactions. Previous research on modeling this context has mainly focused on theoretical models and econometric analyses<sup>[5-8]</sup>, which have not sufficiently dissected the outcomes of enterprises' bidding games among multiple agents and are thus inadequate to systematically explain price formation under competitive dynamics.

## Objective

To extend agent-based simulation model for competitive bidding in China's NVBP and explore its policy implications for procurement optimization.

## Methods

- We developed a multi-agent simulation framework calibrated with real-world data from NVBP rounds 2-9 (excluding Round 6), involving 325 drugs and 2,267 enterprises
- A rule-based Agent-Based Model (ABM) was constructed to simulate bidding of firms under rules
- To address the limitation that rule-based ABMs rely on random single-step actions, we integrated a Markov Decision Process (MDP)
  - ✓ Reinforcement Learning (RL)
  - ✓ Large Language Models (LLMs)
  - ✓ Markup-based pricing algorithm (Rule-based)
- Sensitivity analyses (key policy parameters and market parameters)
  - ✓ Maximum valid bidding price
  - ✓ Agreed procurement volume
  - ✓ ...

### ABM Framework




Fig 1. ABM Framework Overview

### MDP Framework




Fig 2. MDP Framework Overview

## Conclusion

While the ABM approach effectively reproduced real-world bidding outcomes, the MDP extension further enhanced simulation realism and presented interpretable evidence regarding firm's strategic adaptations. These findings highlighted that accurate demand forecasting and rational rule design of maximum bid price were key policy levers for optimizing NVBP in China.

## Results




Fig 3. Density Plot of Winning Price Decline Rates

Fig 4. Box Plot of Winning Price Decline Rates


- The ABM demonstrated good fidelity in reproducing real-world outcomes.
  - ✓ overall RMSE 12.86%

**Table 1. Correlation and Prediction Performance of Different Algorithms**


Algorithm	Spearman $\rho$	Selection prediction accuracy (%)
IPPO	0.87***	74.97(5.35)
MAPPO	0.88***	75.00(5.98)
LLM	0.87***	65.74(3.08)
Rule-Based	0.85***	64.56(4.2)

Notes, Spearman's  $\rho$  indicates the correlation between predicted and actual values. Selection prediction accuracy represents the percentage of correctly predicted selections in simulation. Standard deviations are shown in parentheses. \*\*\*  $p < 0.001$ .

- Simulated bids strongly correlated with actual bids (Spearman  $\rho = 0.85-0.88$ ;  $P < 0.001$ ).



- RL consistently outperforming LLM and Rule-based approaches regarding firm profitability.



Notes, (a,b) agreed procurement ratios ( $\rho$ ); (c,d) maximum valid bidding prices ( $P_{max}$ ) (unit: CNY); (e,f) agreed procurement volume ( $Q_a$ ) (unit:  $10^3$  dosage units); (g,h) actual procurement volume ( $Q_a$ ) (unit:  $10^3$  dosage units); (i,j) unit production costs ( $C_i$ ) (unit: CNY). Colored bar indicate four algorithms.

- The maximum valid bid price as the most influential policy parameter affecting bidding behavior, whereas the agreed procurement ratio had limited impact.
- Firm profits were highly sensitive to deviations between actual and agreed procurement volumes

## References

- Xinhuanet. Over 400 billion rmb saved: A closer look at the impact of china's drug procurement program[EB/OL].
- Zheng Zhu, et al. BMJ Global Health, 8, 2023.
- Zheng Zhu, et al. [J]. Pharmacoeconomics and Policy, 1(2):63-72, 2025
- ChinaDaily. National volume based procurement to effectively reduce the burden of medical care 2023 [EB/OL].
- Shengmao Cao, et al. [J]. American Economic Journal: Economic Policy, 16(3):481-513, August 2024.
- Wang J, Yang Y, Xu L, et al. [J]. BMJ Open, 2022, 12(3): e054346.
- Wang N, Yang Y, Xu L, et al [J]. BMC Public Health, 2021, 21(1): 1883.
- Yang Y, Hu R, Geng X, et al. [J]. The International Journal of Health Planning and Management, 2022, 37(3): 1650-1662.

## Contacts

- Bao Liu, Professor, E-mail: [liub@fudan.edu.cn](mailto:liub@fudan.edu.cn).
- Zhongyu Wei, Associate Professor, E-mail: [zywei@fudan.edu.cn](mailto:zywei@fudan.edu.cn).
- Chao He, Researcher, E-mail: [hec\\_tjtt@Tongji.edu.cn](mailto:hec_tjtt@Tongji.edu.cn).